Triptans Today: Their Role in Contemporary Migraine Treatment

Day 5 (2025)

Video Preview

You are currently watching a preview of this interview. Unlock the full version by upgrading to an Access Pass bundle! Get FREE access to 8 expert interviews from Day 1 and Day 2 when you register today!

Key Questions

What are triptans, and how does a patient decide which one to take?
What are the different routes of administration for triptans?
What is the maximum recommended dosage of triptans within a 24-hour period?
Which medications can be taken with triptans while minimizing interactions and side effects?
What does the term “therapeutic window” mean?
Can triptans be used to treat other headache disorders?
Are triptans safe to use during pregnancy and breastfeeding?
Can children and adolescents safely use triptans?
Are there long-term effects of using triptans for extended periods (e.g., decades)?
Are there any conditions or risk factors that contraindicate triptan use?

Interview Notes

Treatments Mentioned

Almotriptan
Analgesics
Anti-inflammatories
Anti-nausea medication
Benzodiazepines
CGRP small-molecule receptor antagonists (gepants)
Ditans (selective 5HT1F receptor agonists)
Eletriptan
Frovatriptan
Hormonal contraceptives
Lasmiditan (Reyvow)
Naproxen
Naratriptan
Rimegepant (Nurtec ODT, Vydrua)
Rizatriptan
Selective serotonin and norepinephrine reuptake inhibitors (SNRIs)
Selective serotonin reuptake inhibitors (SSRIs)
Sumatriptan
Sumatriptan and naproxen sodium (Treximet)
Triptans
Ubrogepant (Ubrelvy)
Zavegepant (Zavzpret)
Zolmitriptan

Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.

Expert

Patricia Pozo-Rosich, MD, PhD

Head of the Neurology Department
Vall d’Hebron University Hospital and Institute of Research

Patricia Pozo-Rosich, MD, PhD, is a neurologist and one of Europe’s leading migraine experts. She leads the Neurology Department at Vall d’Hebron University Hospital in Barcelona and directs the Migraine Adaptive Brain Center, a national reference center focused on advancing migraine research and care. She also heads the Headache Research Laboratory at the Vall d’Hebron Institute of Research (VHIR) and serves as president-elect of the International Headache Society.

Dr. Pozo-Rosich is deeply committed to helping people understand migraine as a complex neurological disorder and improving access to effective treatment. She founded the Spanish-language education site MiDolordeCabeza.org and has authored more than 250 scientific publications. Her work has received multiple national awards, and she serves as associate editor for leading headache journals. She has been principal investigator in more than 100 clinical trials and is an active member of international headache genetics consortiums.